NCT00384904View on ClinicalTrials.gov

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
HIV Infections
Interventions
DRUG

Atazanavir/Ritonavir

Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.

DRUG

Atazanavir/Ritonavir + Famotidine

Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.

DRUG

Atazanavir/Ritonavir + Famotidine

Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.

DRUG

Atazanavir/Ritonavir

Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.

DRUG

Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine

Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.

DRUG

Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine

Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.

Trial Locations (4)

19104

Local Institution, Philadelphia

27599

Unc Center For Aids Research, Chapel Hill

08043

Garden State Infectious Disease Associates, Pa, Voorhees Township

SW10 9TH

Local Institution, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY